| Literature DB >> 32777862 |
Kohei Nozaki1, Nobuaki Hamazaki1, Shohei Yamamoto2,3, Kentaro Kamiya3,4, Shinya Tanaka5, Takafumi Ichikawa1, Takeshi Nakamura3, Masashi Yamashita3, Emi Maekawa6, Atsuhiko Matsunaga3,4, Minako Yamaoka-Tojo3,4, Junya Ako6.
Abstract
AIMS: The area of the pupil can be used as an indicator of autonomic function. However, the relation between pupil area and prognosis in heart failure (HF) patients remains unclear. This study was performed to examine whether pupil area can be used as a prognostic indicator in patients with HF. METHODS ANDEntities:
Keywords: All-cause mortality; Autonomic; Heart failure; Prognosis; Pupil area
Mesh:
Year: 2020 PMID: 32777862 PMCID: PMC7524244 DOI: 10.1002/ehf2.12933
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Patient characteristics stratified according to pupil area
| Overall ( | Small pupil area ( | Large pupil area ( |
| |
|---|---|---|---|---|
| Age (years) | 67.0 ± 14.1 | 69.8 ± 10.8 | 64.5 ± 14.9 | <0.001 |
| Female (%) | 322 (37.0) | 155 (35.7) | 167 (38.3) | 0.587 |
| Height (cm) | 160.7 ± 10.1 | 159.7 ± 10.0 | 161.8 ± 10.2 | 0.403 |
| Body weight (kg) | 57.8 ± 14.2 | 56.3 ± 12.2 | 59.4 ± 15.9 | <0.001 |
| BMI (kg/m2) | 22.3 ± 5.5 | 22.1 ± 4.8 | 22.6 ± 6.1 | 0.011 |
| SBP (mmHg) | 118 ± 29 | 119 ± 29 | 116 ± 28 | 0.738 |
| DBP (mmHg) | 69 ± 19 | 68 ± 19 | 70 ± 19 | 0.291 |
| HR (bpm) | 82 ± 20 | 81 ± 20 | 83 ± 21 | 0.244 |
| Non‐SR (%) | 286 (32.9) | 157 (36.2) | 129 (29.6) | 0.036 |
| LVEF (%) | 47.4 ± 16.9 | 47.8 ± 16.9 | 47.1 ± 16.9 | 0.870 |
| LVEF < 40% | 316 (36.3) | 154 (35.3) | 163 (37.5) | 0.578 |
| LVEF ≥ 50% | 429 (49.3) | 215 (49.3) | 214 (49.2) | 0.867 |
| NYHA functional class | ||||
| I/II | 693 (79.7) | 328 (75.2) | 365 (83.7) | 0.028 |
| III/IV | 177 (20.3) | 106 (24.4) | 71 (16.3) | < 0.001 |
| SHFS | 0.95 (0.41–1.57) | 1.09 (0.56–1.67) | 0.76 (0.22–1.44) | <0.001 |
| Pupil area (mm2) | 16.6 (12.0–21.8) | 11.9 (8.9–14.2) | 21.8 (19.2–26.0) | <0.001 |
| Medications (%) | ||||
| ACE inhibitor or ARB | 700 (80.4) | 354 (81.6) | 346 (79.4) | 0.588 |
| Beta‐blocker | 637 (73.2) | 315 (72.6) | 322 (73.9) | 0.934 |
| Aldosterone blockers | 411 (47.2) | 189 (43.5) | 222 (50.9) | 0.097 |
| Diuretic agents | 680 (78.2) | 344 (79.3) | 336 (77.1) | 0.644 |
| Statin | 398 (45.7) | 223 (51.4) | 175 (40.1) | 0.061 |
| Comorbidities (%) | ||||
| Hypertension | 518 (59.5) | 277 (63.8) | 241(55.3) | 0.102 |
| Diabetes mellitus | 301 (34.6) | 177 (40.8) | 124 (28.4) | 0.078 |
| Dyslipidaemia | 377 (43.3) | 199 (45.9) | 178 (40.8) | 0.127 |
| Atrial fibrillation | 236 (27.1) | 130 (30.0) | 106 (24.3) | 0.067 |
| Ischaemic aetiology | 278 (32.0) | 138 (31.8) | 140 (32.0) | <0.001 |
| Prior HF admission | 366 (42.1) | 197 (45.4) | 169 (38.8) | 0.045 |
| Current smoker (%) | 154 (17.7) | 58 (13.4) | 96 (22.0) | 0.001 |
| Laboratory data | ||||
| Haemoglobin (g/dL) | 11.9 (10.4–13.7) | 11.5 (10.2–13.4) | 12.2 (10.6–14.1) | <0.001 |
| Albumin (g/dL) | 3.6 (3.2–3.9) | 3.6 (3.2–3.9) | 3.6 (3.2–4.0) | 0.445 |
| LDL cholesterol (mg/dL) | 92.0 (72.0–114.0) | 87.0 (68.5–108.0) | 98.0 (77.0–119.5) | <0.001 |
| Sodium (mEq/L) | 139.0 (136.8–140.0) | 139.0 (136.0–140.0) | 139.0 (137.0–140.0) | 0.691 |
| eGFR (mL/min/1.73 m2) | 51.0 (35.0–65.0) | 46.0 (31.6–59.6) | 56.5 (40.0–68.4) | <0.001 |
| hs‐CRP (mg/dL) | 0.32 (0.1–1.0) | 0.34 (0.11–1.04) | 0.30 (0.10–0.93) | 0.426 |
| BNP (pg/mL) | 294.9 (134.0–639.5) | 311.8 (155.8–657.8) | 268.7 (114.8–599.6) | 0.027 |
| All‐cause mortality (%) | 131 (15.0) | 87 (20.0) | 44 (10.1) | <0.001 |
| Cardiovascular death (%) | 90 (10.3) | 61 (14.1) | 29 (6.7) | <0.001 |
| Readmission due to HF (%) | 328 (37.7) | 205 (47.2) | 123 (28.2) | <0.001 |
ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B‐type natriuretic peptide; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, heart rate; hs‐CRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure; SHFS, Seattle Heart Failure Score; SR, sinus rhythm.
Figure 1Kaplan–Meire curve for all‐cause mortality and readmission due to HF according to pupil area. Survival rate was significantly poorer and rate of readmission due to HF was significantly higher in the small pupil area group than the large pupil area group. HF, heart failure.
Univariate and multivariate Cox regression models for all‐cause mortality and readmission due to HF
| Univariate | Model 1 | Model 2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| HR | 95% CI |
| |
| All‐cause mortality | 0.62 | 0.51–0.75 | <0.001 | 0.69 | 0.57–0.84 | <0.001 | 0.72 | 0.59–0.88 | 0.001 |
| Readmission due to HF | 0.72 | 0.65–0.82 | <0.001 | 0.78 | 0.70–0.88 | <0.001 | 0.82 | 0.73–0.93 | 0.003 |
Model 1 was adjusted by Seattle Heart Failure Score, whereas Model 2 was adjusted by Seattle Heart Failure Score, body mass index, B‐type natriuretic peptide, and estimated glomerular filtration rate.
CI, confidence interval; HF, heart failure; HR, hazard ratio.
Figure 2Restricted cubic spline of associations of pupil area and all‐cause mortality. Dotted lines represent the 95% confidence intervals. Rug plots are shown along the x‐axes of the graphs to depict the distributions of pupil area. Hazard ratios were estimated from Cox proportional hazards models. CI, confidence interval.
Figure 3Forest plots of subgroup analyses of the associations between pupil area and all‐cause mortality. All subgroups were adjusted for the Seattle Heart Failure Score, body mass index, log B‐type natriuretic peptide, and eGFR. CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; SR, sinus rhythm.
Figure 4Receiver‐operating characteristic curves of SHFS only and SHFS plus pupil area for all‐cause mortality. The AUC of SHFS plus pupil area was significantly greater than that of SHFS only. AUC, area under the curve; SHFS, Seattle Heart Failure Score.